drugset / Trial / NCT00830128

A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia

NCT00830128

Phase 3 Completed 106 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will assess the safety and efficacy of the long-term use of pregabalin at doses up to 450 mg/day in patients with fibromyalgia who have completed 16 weeks of dosing in Study A0081208 (NCT00830167).

Timeline

Start
2009-07
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 300 mg Oral
Subject Pregabalin Small molecule 450 mg Oral

Indications